Autologous hematopoietic SCT (auto-HSCT) provides hematopoietic support after high-dose
chemotherapy and is the standard of care for patients with multiple myeloma (MM) or …

Hematopoietic stem cell transplantation has been extensively exploited as a therapeutic and
research modality and has revolutionized current patient care. At present, more and more …

Although tissue engineering promises to replace or restore lost function to nearly every
tissue in the body, successful applications are currently limited to tissue less than 2 mm in …

Optimal numbers of CD34+ cells to be reinfused in patients undergoing peripheral blood
progenitor cell (PBPC) transplantation after high-dose chemotherapy are still unknown …

Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used
in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor …

The safety and optimal dose and schedule of stem cell factor (SCF) administered in
combination with filgrastim for the mobilization of peripheral blood progenitor cells (PBPCs) …

Ro 25‐8315 is produced by conjugation of rhG‐CSF mutant with polyethylene glycol (PEG).
The purpose of this study was to examine the pharmacodynamics and pharmacokinetics of …

This randomized, controlled study compared the ability to mobilize and collect an optimal
target yield of 5× 10 6 CD34+ cells/kg using stem cell factor (SCF; 20 μg/kg/day) plus …

This randomized study compared the number of leukaphereses required to collect an
optimal target yield of 5× 106CD34+ peripheral blood progenitor cells/kg, using either stem …

Background: We analyzed the hematopoietic reconstitution and outcome of 508 patients
with multiple myeloma (MM) with respect to the number of CD34+ cells reinfused at our …